Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.

Sy SKB, Chia YL, Gordi T, Hoch U, Eldon MA.

Cancer Chemother Pharmacol. 2018 May;81(5):897-909. doi: 10.1007/s00280-018-3562-3. Epub 2018 Mar 21.

2.

Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy.

Singh P, Rong H, Gordi T, Bosley J, Bhattacharya I.

Clin Transl Sci. 2016 Dec;9(6):302-310. doi: 10.1111/cts.12420. Epub 2016 Oct 4.

3.

Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.

Custodio JM, Gordi T, Zhong L, Ling KH, Ramanathan S.

J Clin Pharmacol. 2016 Jun;56(6):723-32. doi: 10.1002/jcph.657. Epub 2015 Dec 21.

PMID:
26449283
4.

Pharmacokinetic analysis of 14C-ursodiol in newborn infants using accelerator mass spectrometry.

Gordi T, Baillie R, Vuong le T, Abidi S, Dueker S, Vasquez H, Pegis P, Hopper AO, Power GG, Blood AB.

J Clin Pharmacol. 2014 Sep;54(9):1031-7. doi: 10.1002/jcph.327. Epub 2014 May 20.

PMID:
24805288
5.

Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms.

Cowles VE, Gordi T, Hou SY.

Clin Drug Investig. 2012 Sep 1;32(9):593-601. doi: 10.2165/11634520-000000000-00000.

PMID:
22775354
6.

Drug discovery and development: lessons from an undeveloped drug.

Gordi T.

Expert Rev Clin Pharmacol. 2012 Mar;5(2):157-62. doi: 10.1586/ecp.11.76.

PMID:
22390558
7.

Artemisinin derivatives with long elimination half-life.

Gordi T.

J Pharm Pharmacol. 2008 Oct;60(10):1277-8. doi: 10.1211/jpp/60.10.0002. No abstract available.

PMID:
18812019
8.

Clinical development of metformin extended-release tablets for type 2 diabetes: an overview.

Schwartz SL, Gordi T, Hou E, Cramer M, Heritier M, Cowles VE.

Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1235-43. doi: 10.1517/17425255.4.9.1235.

PMID:
18721117
9.

Artesunate for malaria.

Gordi T.

N Engl J Med. 2008 Jul 17;359(3):313; author reply 314-5. No abstract available.

PMID:
18642414
11.

Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen.

Obua C, Hellgren U, Ntale M, Gustafsson LL, Ogwal-Okeng JW, Gordi T, Jerling M.

Br J Clin Pharmacol. 2008 Apr;65(4):493-501. doi: 10.1111/j.1365-2125.2007.03050.x. Epub 2008 Feb 20.

12.

Comments on "Dual effects of rifampin on the pharmacokinetics of atrasentan".

Gordi T.

J Clin Pharmacol. 2007 Sep;47(9):1181; author reply 1182. No abstract available.

PMID:
17766702
13.

Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans.

Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, Belardinelli L, Kerensky RA.

J Nucl Cardiol. 2007 Jul;14(4):514-20.

PMID:
17679059
14.

Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.

Gordi T, Blackburn B, Lieu H.

J Clin Pharmacol. 2007 Jul;47(7):825-33.

PMID:
17585115
15.
16.

A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.

Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H.

Clin Pharmacokinet. 2006;45(12):1201-12.

PMID:
17112296
17.

Are currently deployed artemisinins neurotoxic?

Adjei GO, Goka BQ, Kurtzhals JA, Gordi T.

Toxicol Lett. 2006 Dec 1;167(2):162-4; author reply 165-6. Epub 2006 Sep 12. No abstract available.

PMID:
17049764
18.
19.

CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations.

Xie R, Tan LH, Polasek EC, Hong C, Teillol-Foo M, Gordi T, Sharma A, Nickens DJ, Arakawa T, Knuth DW, Antal EJ.

J Clin Pharmacol. 2005 Mar;45(3):352-6. No abstract available.

PMID:
15703370
20.
21.

Simple solution to a common statistical problem: interpreting multiple tests.

Gordi T, Khamis H.

Clin Ther. 2004 May;26(5):780-6.

PMID:
15220022
22.

Artemisinin derivatives: toxic for laboratory animals, safe for humans?

Gordi T, Lepist EI.

Toxicol Lett. 2004 Mar 1;147(2):99-107. Review.

PMID:
14757313
23.

The pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E.

Gordi T, Tan LH, Hong C, Hopkins NJ, Francom SF, Slatter JG, Antal EJ.

J Clin Pharmacol. 2003 Oct;43(10):1161-7.

PMID:
14517199
24.

Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens.

Gordi T, Huong DX, Hai TN, Nieu NT, Ashton M.

Antimicrob Agents Chemother. 2002 Apr;46(4):1026-31.

25.

Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin.

Gordi T, Hai TN, Hoai NM, Thyberg M, Ashton M.

Eur J Clin Pharmacol. 2000 Nov;56(8):561-6.

PMID:
11151745
26.

Direct analysis of artemisinin in plasma and saliva using coupled-column high-performance liquid chromatography with a restricted-access material pre-column.

Gordi T, Nielsen E, Yu Z, Westerlund D, Ashton M.

J Chromatogr B Biomed Sci Appl. 2000 May 26;742(1):155-62.

PMID:
10892594
27.

Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses.

Ashton M, Gordi T, Trinh NH, Nguyen VH, Nguyen DS, Nguyen TN, Dinh XH, Johansson M, Le DC.

Biopharm Drug Dispos. 1998 May;19(4):245-50.

PMID:
9604124
28.

Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria.

Ashton M, Nguyen DS, Nguyen VH, Gordi T, Trinh NH, Dinh XH, Nguyen TN, Le DC.

Clin Pharmacol Ther. 1998 Apr;63(4):482-93.

PMID:
9585803
29.

Supplemental Content

Support Center